We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.51%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.25B
AUM Growth
-$409M
Cap. Flow
-$35.9M
Cap. Flow %
-2.87%
Top 10 Hldgs %
50.14%
Holding
212
New
40
Increased
31
Reduced
43
Closed
54

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.5M
2
RGNX icon
Regenxbio
RGNX
+$19.9M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$15.6M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$14.2M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$12.7M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$19M
2
AGN
Allergan plc
AGN
+$18M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$17.5M
4
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$17M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Consumer Discretionary 0.07%
3 Financials 0.04%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
26
DELISTED
Dermira, Inc.
DERM
$11M 0.88%
472,000
+320,000
+211% +$7.77M
DBVT
27
DBV Technologies
DBVT
$813M
$10.9M 0.87%
30,672
+30,372
+10,124% +$11.9M
NVO
28
PUT
Novo Nordisk
NVO
$228B
$10.8M 0.87%
+400,000
New +$11.3M
QTNT
29
DELISTED
Quotient Limited Ordinary Shares
QTNT
$10.3M 0.83%
19,420
+5,359
+38% +$3.35M
GILD icon
30
PUT
Gilead Sciences
GILD
$165B
$9.82M 0.78%
100,000
-100,000
-50% -$11.1M
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$4.51B
$9.76M 0.78%
295,240
-115,000
-28% -$4.78M
SRPT icon
32
CALL
Sarepta Therapeutics
SRPT
$1.64B
$9.63M 0.77%
300,000
-200,000
-40% -$6.79M
CDTX
33
DELISTED
Cidara Therapeutics
CDTX
$9.45M 0.75%
37,143
+22,143
+148% +$6.33M
EGRX
34
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$9.11M 0.73%
123,044
-110,000
-47% -$9.15M
TEVA icon
35
Teva Pharmaceuticals
TEVA
$40.4B
$9.03M 0.72%
+160,000
New +$10.4M
BPMC
36
DELISTED
Blueprint Medicines
BPMC
$8.63M 0.69%
404,404
– –
VBIV
37
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$8.61M 0.69%
108,679
+21,667
+25% +$1.72M
SHPG
38
DELISTED
Shire pic
SHPG
$8.41M 0.67%
41,000
+1,000
+3% +$238K
ZYNE
39
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$8.29M 0.66%
+579,350
New +$14.2M
NEOS
40
DELISTED
Neos Therapeutics, Inc
NEOS
$7.8M 0.62%
+371,066
New +$8.18M
ASMB icon
41
Assembly Biosciences
ASMB
$498M
$7.6M 0.61%
66,250
+842
+1% +$148K
BLCM
42
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$7.57M 0.6%
52,119
-3,144
-6% -$577K
NEPT
43
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$7.37M 0.59%
4,786
– –
ABEO icon
44
Abeona Therapeutics
ABEO
$355M
$7.14M 0.57%
70,515
+51,715
+275% +$6.86M
XLRN
45
DELISTED
Acceleron Pharma
XLRN
$6.87M 0.55%
276,036
– –
THOR
46
CALL
DELISTED
THORATEC CORPORATION
THOR
$6.33M 0.51%
100,000
– –
ADYX
47
DELISTED
Adynxx Inc
ADYX
$6.09M 0.49%
32,033
– –
CLLS
48
Cellectis
CLLS
$288M
$5.76M 0.46%
218,679
+37,179
+20% +$1.24M
AGTC
49
DELISTED
Applied Genetic Technologies Corporation
AGTC
$5.59M 0.45%
850,992
+550,070
+183% +$9.12M
NDRM
50
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$5.58M 0.45%
270,000
+70,000
+35% +$1.44M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Perceptive Advisors held 212 positions worth $1.25B, down 25% from $1.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q3 2015 filing shows 40 new, 31 increased, 43 reduced and 54 closed positions. Its largest new stake was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M. The largest sale was ZS PHARMA INC COMS TK (DE), an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Perceptive Advisors's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2015, an estimated $15.6M increase.
  • Perceptive Advisors's biggest Q3 2015 reduction was ANI Pharmaceuticals, cutting an estimated $17.5M.
  • Perceptive Advisors fully exited ZS PHARMA INC COMS TK (DE) in Q3 2015, selling an estimated $19M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.25B portfolio in Q3 2015.
  • Perceptive Advisors opened 40 new positions and closed 54 in Q3 2015.
  • Perceptive Advisors's portfolio value fell 25% quarter-over-quarter to $1.25B.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.